Sanofi (MEX:SAN1N) EBIT: MXN145,852 Mil (TTM As of Dec. 2025)


MEX:SAN1N Sanofi SA MEX:SAN1N
72 GF Score
Price MXN1,525.85
GF Value MXN2,212.65
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Sanofi EBIT?

Sanofi MEX:SAN1N 72 EBIT is MXN145,852 Mil as of Dec. 2025. GuruFocus rates MEX:SAN1N with a GF Score™ of 72/100 and a GF Value™ of MXN2,212.65 (Possible Value Trap). The stock has 2 warning signs investors should review.

Sanofi's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was MXN61,544 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was MXN145,852 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sanofi's annualized ROC % for the quarter that ended in Dec. 2025 was 8.31%. Sanofi's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 51.10%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sanofi's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 7.07%.


Sanofi  (MEX:SAN1N) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sanofi's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=228718.774 * ( 1 - 12.8% )/( (2371610.495 + 2427880.998)/ 2 )
=199442.770928/2399745.7465
=8.31 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2713815.459 - 169375.929 - ( 333561.341 - max(0, 631093.106 - 803922.141+333561.341))
=2371610.495

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2673551.275 - 190704.399 - ( 178517.871 - max(0, 597624.785 - 652590.663+178517.871))
=2427880.998

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Sanofi's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=123088.146/( ( (239046.141 + max(-5147.0820000001, 0)) + (242697.439 + max(-81847.925, 0)) )/ 2 )
=123088.146/( ( 239046.141 + 242697.439 )/ 2 )
=123088.146/240871.79
=51.10 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(169614.824 + 208880.329 + 83243.742) - (169375.929 + 0 + 297510.048)
=-5147.0820000001

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(177316.085 + 215351.545 + 25827.849) - (190704.399 + 0 + 309639.005)
=-81847.925

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sanofi's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=145851.979/2063461.131
=7.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sanofi EBIT Related Terms


Sanofi EBIT Historical Data

* Premium members only.

The historical data trend for Sanofi's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi EBIT Chart

Sanofi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 189,771.89 214,827.75 127,612.29 161,648.05 143,392.00

Sanofi Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43,314.88 56,123.80 99,495.88 84,307.91 61,544.07

MEX:SAN1N vs LLY, JNJ, ABBV: EBIT Comparison

For the Drug Manufacturers - General subindustry, Sanofi's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanofi EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sanofi's EV-to-EBIT falls into.


MEX:SAN1N
72GF Score
Sanofi SA MEX:SAN1N
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was MXN145,852 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of MXN145,852 Mil mean?
Sanofi (MEX:SAN1N) has a EBIT of MXN145,852 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sanofi.
Is Sanofi's EBIT too high?
Sanofi's current EBIT is MXN145,852 Mil. Overall, Sanofi has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanofi's EBIT compare to LLY and JNJ?
Sanofi's EBIT of MXN145,852 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sanofi. Sanofi's current EBIT is MXN145,852 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Based on GuruFocus' analysis, Sanofi (MEX:SAN1N) is currently considered Possible Value Trap. The stock's GF Value™ is MXN2,212.65, compared to a current price of MXN1,525.85 — trading 31% below its estimated fair value. The current EBIT is MXN145,852 Mil. Sanofi's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sanofi (MEX:SAN1N), the current EBIT is MXN145,852 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanofi (MEX:SAN1N) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi stock appears to be undervalued. The current stock price of MXN1,525.85 is trading 31% below its estimated GF Value™ of MXN2,212.65. GuruFocus considers Sanofi to be Possible Value Trap.

Key valuation signals for MEX:SAN1N:

  • EBIT: MXN145,852 Mil
  • GF Value™: MXN2,212.65 vs. price of MXN1,525.85 (31% below fair value)
  • GF Score™: 72/100 with 2 warning signs

No single metric tells the full story. See the MEX:SAN1N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sanofi Business Description

Address 46, Avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
72GF Score

Get the complete analysis for MEX:SAN1N

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,525.85
Price
MXN2,212.65
GF Value